Published in Clinical Oncology Week, May 26th, 2008
"We identified the A-type cyclin, cyclin At as an important downstream target of P13K/Akt. Treatment of cells with P13K inhibitor or cotransfection with a vector expressing wild-type PTEN decreased cyclin At promoter activity. Cyclin At promoter activity and its expression were upregulated by constitutively...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.